Potential radiopharmaceuticals for the diagnosis of biliary atresia and neonatal hepatitis: EHPG and HBED chelates of 67Ga and 111In |
| |
| Institution: | 1. NURA Research Group, Belgian Nuclear Research Center (SCK CEN), Mol, Belgium;2. Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, University of Leuven, Leuven, Belgium;3. Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University of Leuven, Leuven, Belgium;4. Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands;5. Nuclear Medicine, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium;6. Department of Chemistry, University of Leuven, Leuven, Belgium;1. Institut Jules Bordet—Université Libre de Bruxelles (ULB), Brussels, Belgium;2. University of Groningen, University Medical Center Groningen, Groningen, The Netherlands;3. Antwerp University Hospital, Antwerpen, Belgium;4. Radboud University Medical Center Nijmegen, Nijmegen;5. VU University Medical Center Amsterdam, Amsterdam, The Netherlands |
| |
| Abstract: | Radiopharmaceuticals suitable for use in cases where delayed excretion of hepatobiliary tracer can occur, were formulated from indium-111 and gallium-67 and the chelating agents N,N′-ethylene-bis-o-hydroxyphenylglycine], (EHPG) and N,N′-bis-2-hydroxybenzyl] ethylenediamine-N,N′-diacetic acid, (HBED). The hepatobiliary excretion of these 67Ga and 111In chelates was optimised by using chelators which had substituents in the phenolic ring; halogen substituents imparted the most favourable characteristics. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
